AstraZeneca and Daiichi Sankyo's Breast Cancer Drug Approved for NHS in England
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Women with an aggressive form of breast cancer in England will finally get access to a drug from AstraZeneca Plc and Daiichi Sankyo Co. on the National Health Service, after an agreement was reached with the regulator.
This approval marks a significant step in providing treatment options for patients battling this challenging disease.
AstraZenecaDaiichi SankyoNational Health Service
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Women with an aggressive form of breast cancer in England will finally get access to a drug from AstraZeneca Plc and Daiichi Sankyo Co. on the National Health Service, after an agreement was reached with the regulator.”
Bloomberg — A Life-Extending Breast Cancer Drug Finally Comes to England